Overview

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

Status:
COMPLETED

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1, open-label, two-period, one-sequence, crossover drug-drug interaction study to assess the P-gp and BCRP inhibition potential of divarasib using digoxin and rosuvastatin as probe substrates, respectively, in healthy participants.

Phase:

PHASE1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Digoxin
Rosuvastatin Calcium